PT3024826T - Novos compostos de isoindolina ou de isoquinolina, um processo para a sua preparação e composições farmacêuticas que os contêm - Google Patents

Novos compostos de isoindolina ou de isoquinolina, um processo para a sua preparação e composições farmacêuticas que os contêm

Info

Publication number
PT3024826T
PT3024826T PT14741648T PT14741648T PT3024826T PT 3024826 T PT3024826 T PT 3024826T PT 14741648 T PT14741648 T PT 14741648T PT 14741648 T PT14741648 T PT 14741648T PT 3024826 T PT3024826 T PT 3024826T
Authority
PT
Portugal
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
isoquinoline compounds
new isoindoline
Prior art date
Application number
PT14741648T
Other languages
English (en)
Portuguese (pt)
Inventor
De Nanteuil Guillaume
Geneste Olivier
Fejes Imre
Le Tiran Arnaud
Le Diguarher Thierry
Starck Jérôme-Benoît
Henlin Jean-Michel
Guillouzic Anne-Françoise
Edward Paul Davidson James
Brooke Murray James
Kotschy Andras
Chen I-Jen
Walmsley Claire
Dodsworth Mark
W G Meissner Johannes
Brough Paul
Tatai Janos
Nyerges Miklos
Szlavik Zoltan
Original Assignee
Servier Lab
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Vernalis R&D Ltd filed Critical Servier Lab
Publication of PT3024826T publication Critical patent/PT3024826T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/10X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
PT14741648T 2013-07-23 2014-07-22 Novos compostos de isoindolina ou de isoquinolina, um processo para a sua preparação e composições farmacêuticas que os contêm PT3024826T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1357276A FR3008977A1 (fr) 2013-07-23 2013-07-23 Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
PT3024826T true PT3024826T (pt) 2019-01-28

Family

ID=49911606

Family Applications (1)

Application Number Title Priority Date Filing Date
PT14741648T PT3024826T (pt) 2013-07-23 2014-07-22 Novos compostos de isoindolina ou de isoquinolina, um processo para a sua preparação e composições farmacêuticas que os contêm

Country Status (49)

Country Link
US (3) US9809574B2 (https=)
EP (1) EP3024826B1 (https=)
JP (1) JP6395829B2 (https=)
KR (1) KR102008431B1 (https=)
CN (2) CN105431422B (https=)
AP (1) AP2016008989A0 (https=)
AR (1) AR097009A1 (https=)
AU (1) AU2014295101B2 (https=)
BR (1) BR112016001080B1 (https=)
CA (1) CA2919572C (https=)
CL (1) CL2016000148A1 (https=)
CR (1) CR20160030A (https=)
CU (1) CU24352B1 (https=)
CY (1) CY1121247T1 (https=)
DK (1) DK3024826T3 (https=)
DO (1) DOP2016000009A (https=)
EA (1) EA032301B1 (https=)
ES (1) ES2711371T3 (https=)
FR (1) FR3008977A1 (https=)
GE (2) GEP20207070B (https=)
HK (1) HK1218754A1 (https=)
HR (1) HRP20190277T1 (https=)
HU (1) HUE041443T2 (https=)
IL (1) IL243449A0 (https=)
JO (1) JO3457B1 (https=)
LT (1) LT3024826T (https=)
MA (1) MA38801B1 (https=)
MD (1) MD4793C1 (https=)
ME (1) ME03346B (https=)
MX (1) MX365373B (https=)
MY (1) MY193619A (https=)
NI (1) NI201600016A (https=)
NZ (1) NZ716155A (https=)
PE (1) PE20160241A1 (https=)
PH (1) PH12016500034A1 (https=)
PL (1) PL3024826T3 (https=)
PT (1) PT3024826T (https=)
RS (1) RS58344B1 (https=)
RU (1) RU2689305C2 (https=)
SA (1) SA516370439B1 (https=)
SG (1) SG11201600205XA (https=)
SI (1) SI3024826T1 (https=)
TN (1) TN2016000003A1 (https=)
TR (1) TR201819155T4 (https=)
TW (1) TWI560184B (https=)
UA (1) UA117490C2 (https=)
UY (1) UY35664A (https=)
WO (1) WO2015011164A1 (https=)
ZA (1) ZA201600198B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3008977A1 (fr) * 2013-07-23 2015-01-30 Servier Lab Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
BR112018071548A2 (pt) 2016-04-20 2019-04-16 Bristol-Myers Squibb Company compostos heterocíclicos bicíclicos substituídos
BR112020026580A2 (pt) 2018-06-27 2021-03-23 Proteostasis Therapeutics, Inc. (Fem) Compostos, composição farmacêutica e métodos para tratar um paciente
KR20220102622A (ko) * 2019-11-15 2022-07-20 우한 엘엘 사이언스 앤드 테크놀로지 디벨롭먼트 컴퍼니, 리미티드 Rock 억제제 및 이의 제조 방법과 용도
CN112010796B (zh) * 2020-09-17 2022-04-22 浙江大学 光学活性3-(1,1-二氟-2-氧-2-芳基乙基)异吲哚啉-1-酮衍生物制备方法
JP2024511277A (ja) 2021-02-19 2024-03-13 メビオン・メディカル・システムズ・インコーポレーテッド 粒子線治療システムのためのガントリー
CN116997544A (zh) * 2021-03-24 2023-11-03 法国施维雅药厂 用于合成5-{5-氯-2-[(3s)-3-[(吗啉-4-基)甲基]-3,4-二氢异喹啉-2(1h)-羰基]苯基}-1,2-二甲基-1h-吡咯-3-甲酸衍生物的新方法及其在生产药物化合物中的应用
US20250179047A1 (en) 2022-02-24 2025-06-05 Les Laboratoires Servier 5-[7-(3,4-dihydro-1h-isoquinoline-2-carbonyl)-1,2,3,4 tetrahydroisoquinolin-6-yl]-1h-pyrrole-3-carboxamide derivatives, pharmaceutical compositions containing them and their uses as pro-apoptotic agents
CN120787162A (zh) 2022-05-20 2025-10-14 诺华股份有限公司 抗肿瘤化合物的抗体-药物缀合物及其使用方法
WO2024204846A1 (ja) * 2023-03-31 2024-10-03 三井化学株式会社 カルバメート化合物
PY24103486A (es) 2023-11-22 2025-06-06 Servier Lab Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos
TW202540186A (zh) 2023-11-22 2025-10-16 瑞士商諾華公司 抗cd7抗體藥物結合物及其使用方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1501514B1 (en) 2002-05-03 2012-12-19 Exelixis, Inc. Protein kinase modulators and methods of use
WO2004096774A1 (en) * 2003-05-01 2004-11-11 Glaxo Group Limited Acyl isoindoline derivatives and acyl isoquinoline derivatives as anti-viral agents
US20050070570A1 (en) 2003-06-18 2005-03-31 4Sc Ag Novel potassium channels modulators
CA2577752A1 (en) * 2004-08-20 2006-03-02 The Regents Of The University Of Michigan Small molecule inhibitors of anti-apoptotic bcl-2 family members and the uses thereof
EP1778206A4 (en) * 2004-08-20 2009-08-05 Univ Michigan SMALL MOLECULE INHIBITORS FROM MEMBERS OF THE ANTIOPTOTIC BCL-2 FAMILY AND USES THEREOF
WO2006087309A1 (en) * 2005-02-15 2006-08-24 Novo Nordisk A/S 3,4-dihydro-1h-isoquinoline-2-carboxylic acid 5-aminopyridin-2-yl esters
KR101511074B1 (ko) 2007-04-16 2015-04-13 애브비 인코포레이티드 7-치환된 인돌 Mcl-1 억제제
AU2008334075A1 (en) 2007-11-30 2009-06-11 Biota Scientific Management Pty Ltd Tetrahydro-isoquinoline PPAT inhibitors as antibacterial agents
JP5496915B2 (ja) 2008-02-13 2014-05-21 シージーアイ ファーマシューティカルズ,インコーポレーテッド 6−アリール−イミダゾ[1,2−a]ピラジン誘導体、その製造方法、及びその使用方法
WO2009102463A2 (en) 2008-02-14 2009-08-20 Connor Reynolds Pet waste vacuum system and apparatus, disposable liners therefor, and a method of collecting pet waste using same
CN103732589B (zh) * 2011-05-25 2016-03-30 百时美施贵宝公司 可用作抗细胞凋亡bcl抑制剂的取代的磺酰胺
JP2015503518A (ja) * 2011-12-23 2015-02-02 ノバルティス アーゲー Bcl2と結合相手の相互作用を阻害するための化合物
WO2013100890A1 (en) 2011-12-27 2013-07-04 Intel Corporation Methods and systems to control power gates during an active state of a gated domain based on load conditions of the gated domain
FR2986002B1 (fr) * 2012-01-24 2014-02-21 Servier Lab Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3008977A1 (fr) * 2013-07-23 2015-01-30 Servier Lab Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3008979B1 (fr) * 2013-07-23 2015-07-24 Servier Lab Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
MD4793C1 (ro) 2022-09-30
US20180002313A1 (en) 2018-01-04
MY193619A (en) 2022-10-20
SA516370439B1 (ar) 2019-06-27
EP3024826A1 (en) 2016-06-01
CY1121247T1 (el) 2020-05-29
ME03346B (me) 2019-10-20
SG11201600205XA (en) 2016-02-26
RU2689305C2 (ru) 2019-05-27
CA2919572A1 (en) 2015-01-29
PH12016500034B1 (en) 2016-03-28
MX365373B (es) 2019-05-31
CN105431422A (zh) 2016-03-23
HK1218754A1 (zh) 2017-03-10
AU2014295101B2 (en) 2018-05-31
CN109456324B (zh) 2022-04-22
ES2711371T3 (es) 2019-05-03
CN105431422B (zh) 2019-08-30
ZA201600198B (en) 2019-07-31
AP2016008989A0 (en) 2016-01-31
JP6395829B2 (ja) 2018-09-26
CA2919572C (en) 2017-06-20
KR20160033224A (ko) 2016-03-25
CU24352B1 (es) 2018-07-05
TN2016000003A1 (en) 2017-07-05
HK1222856A1 (en) 2017-07-14
PE20160241A1 (es) 2016-04-30
MX2016000904A (es) 2016-04-25
CU20160010A7 (es) 2016-06-29
TWI560184B (en) 2016-12-01
RS58344B1 (sr) 2019-03-29
EA032301B1 (ru) 2019-05-31
JP2016525529A (ja) 2016-08-25
PH12016500034A1 (en) 2016-03-28
LT3024826T (lt) 2019-02-25
MD20160018A2 (ro) 2016-07-31
DK3024826T3 (en) 2019-03-04
US9809574B2 (en) 2017-11-07
SI3024826T1 (sl) 2019-03-29
US20200262816A1 (en) 2020-08-20
CN109456324A (zh) 2019-03-12
RU2016106003A (ru) 2017-08-28
GEP20207070B (en) 2020-02-25
UY35664A (es) 2015-01-30
AR097009A1 (es) 2016-02-10
CR20160030A (es) 2016-03-09
EP3024826B1 (en) 2018-11-14
PL3024826T3 (pl) 2019-05-31
AU2014295101A1 (en) 2016-02-04
US11028070B2 (en) 2021-06-08
MA38801A1 (fr) 2018-05-31
GEAP201914063A (en) 2019-10-25
US20160194304A1 (en) 2016-07-07
TR201819155T4 (tr) 2019-01-21
CL2016000148A1 (es) 2016-08-12
NZ716155A (en) 2019-05-31
JO3457B1 (ar) 2020-07-05
WO2015011164A1 (en) 2015-01-29
KR102008431B1 (ko) 2019-08-07
HRP20190277T1 (hr) 2019-04-05
MA38801B1 (fr) 2019-03-29
MD4793B1 (ro) 2022-02-28
BR112016001080A2 (https=) 2017-07-25
UA117490C2 (uk) 2018-08-10
BR112016001080B1 (pt) 2022-04-05
FR3008977A1 (fr) 2015-01-30
NI201600016A (es) 2016-02-11
TW201504228A (zh) 2015-02-01
US10689364B2 (en) 2020-06-23
IL243449A0 (en) 2016-02-29
DOP2016000009A (es) 2016-03-15
EA201600122A1 (ru) 2016-07-29
HUE041443T2 (hu) 2019-05-28

Similar Documents

Publication Publication Date Title
PT3024826T (pt) Novos compostos de isoindolina ou de isoquinolina, um processo para a sua preparação e composições farmacêuticas que os contêm
PT3313850T (pt) Novos derivados de aminoácidos, um processo para a sua preparação e composições farmacêuticas que os contêm
BR112013020362A2 (pt) processos para a preparação de compostos de quinolina, compostos e combinações farmacêuticas que os contem
BR112016005262A2 (pt) Compostos aril éteres, uso dos mesmos e composição farmacêutica que os compreende
IL233663B (en) Indolizine compounds, processes for their preparation and pharmaceutical compositions containing them
BR112016000489A2 (pt) composto, composição farmacêutica que o compreende, uso da composição e métodos para fabricar compostos
ZA201405418B (en) New phosphate compounds, a process for their preparation and pharmaceutical compositions containing them
BR112015031979A2 (pt) letermovir, formulação farmacêutica oral sólida, uso de uma formulação farmacêutica oral sólida, e processo para preparar letermovir.
IL243742B (en) New indolizine compounds, a process for their preparation and pharmaceutical compositions containing them
BR112015003101A2 (pt) processo para a preparação de um composto.
BR112015002824A2 (pt) composto, uso de um composto, composição farmacêutica, e, produto farmacêutico de combinação.
SI3735962T1 (sl) Farmacevtska sestava, obsegajoča fosfatne vezivne delce
CL2014002951A1 (es) (r)-nifuratel; formulacion farmaceutica que lo contiene; y proceso para fabricar (r)-nifuratel y (s)-nifuratel.
BR112015010797A2 (pt) compostos aniônicos substituídos, e, composição farmacêutica
BR112016011700A2 (pt) processo aperfeiçoado para a preparação de pomalidomida e sua purificação
HUE041983T2 (hu) Tofogliflozint tartalmazó szilárd készítmények és eljárás ezek elõállítására
EP2994197A4 (en) PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
BR112015014078A2 (pt) composição farmacêutica oftalmológica tópica que contém regorefenib
BR112015000987A2 (pt) processo para a preparação de 5-fluoro-1h-pirazóis
HUE043942T2 (hu) Trimetazidint tartalmazó nyújtott hatóanyagleadású gyógyszerészeti készítmény
PT3022787T (pt) Processo para a preparação de um produto compósito semi-acabado
BR112016011994A2 (pt) composição herbicida de fase líquida única e processo para a preparação da composição
EP2897590A4 (en) PHARMACEUTICAL COMPOSITION
DK2908836T3 (da) Farmaceutisk formulering indeholdende curcuma
PT3271368T (pt) Novos derivados de fosfinano e de azafosfinano, o respetivo processo de produção e as composições farmacêuticas que os contêm